The FDA's classification of BPC-157 under its interim compounding policies for 503A bulk drug substances centers on safety data gaps, immunogenicity risks, and limited human clinical evidence, which placed the peptide in Category 2 in late 2023 and restricted routine compounding. Trader sentiment has shifted with the Pharmacy Compounding Advisory Committee's July 23–24, 2026 vote (8-6 with one abstention) recommending addition to the 503A bulks list despite FDA staff opposition. This advisory step does not automatically trigger reclassification to Category 1, where substances under evaluation generally face no enforcement during review. FDA holds final authority, and any formal move would require agency action following the committee input. No major updates have emerged since the meeting, though resolution timing hinges on FDA's internal review process rather than fixed statutory deadlines.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedNEW
Aug 31, 2026
August 31, 2026
17%
December 31, 2026
51%
$2,409 Vol.
August 31, 2026
$706 Vol.
17%
December 31, 2026
$1,703 Vol.
51%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's classification of BPC-157 under its interim compounding policies for 503A bulk drug substances centers on safety data gaps, immunogenicity risks, and limited human clinical evidence, which placed the peptide in Category 2 in late 2023 and restricted routine compounding. Trader sentiment has shifted with the Pharmacy Compounding Advisory Committee's July 23–24, 2026 vote (8-6 with one abstention) recommending addition to the 503A bulks list despite FDA staff opposition. This advisory step does not automatically trigger reclassification to Category 1, where substances under evaluation generally face no enforcement during review. FDA holds final authority, and any formal move would require agency action following the committee input. No major updates have emerged since the meeting, though resolution timing hinges on FDA's internal review process rather than fixed statutory deadlines.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Market Opened: Jun 22, 2026, 10:10 PM ET
Volume
$2,409End Date
Dec 31, 2026Market Opened
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's classification of BPC-157 under its interim compounding policies for 503A bulk drug substances centers on safety data gaps, immunogenicity risks, and limited human clinical evidence, which placed the peptide in Category 2 in late 2023 and restricted routine compounding. Trader sentiment has shifted with the Pharmacy Compounding Advisory Committee's July 23–24, 2026 vote (8-6 with one abstention) recommending addition to the 503A bulks list despite FDA staff opposition. This advisory step does not automatically trigger reclassification to Category 1, where substances under evaluation generally face no enforcement during review. FDA holds final authority, and any formal move would require agency action following the committee input. No major updates have emerged since the meeting, though resolution timing hinges on FDA's internal review process rather than fixed statutory deadlines.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$2,409End Date
Dec 31, 2026Market Opened
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The FDA's classification of BPC-157 under its interim compounding policies for 503A bulk drug substances centers on safety data gaps, immunogenicity risks, and limited human clinical evidence, which placed the peptide in Category 2 in late 2023 and restricted routine compounding. Trader sentiment has shifted with the Pharmacy Compounding Advisory Committee's July 23–24, 2026 vote (8-6 with one abstention) recommending addition to the 503A bulks list despite FDA staff opposition. This advisory step does not automatically trigger reclassification to Category 1, where substances under evaluation generally face no enforcement during review. FDA holds final authority, and any formal move would require agency action following the committee input. No major updates have emerged since the meeting, though resolution timing hinges on FDA's internal review process rather than fixed statutory deadlines.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions